HRS-5965 clinical trials
Also written HRS-5965.
How each study uses HRS-5965 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS-5965 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test HRS-5965, phase 3 first.
- Oct 2027A Trial of HRS-5965 Capsule in Primary IgA NephropathyPhase 3 · Chengdu Suncadia Medicine Co., Ltd.
Studies
Open first, then newest update. How each study uses HRS-5965 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA NephropathyRecruitingPhase 2Chengdu Suncadia Medicine Co., Ltd.NCT07582133Written as HRS-5965 Capsules
- A Trial of HRS-5965 Capsule in Primary IgA NephropathyRecruitingPhase 3Chengdu Suncadia Medicine Co., Ltd.NCT07014826Written as HRS-5965
- A Trial of HRS-5965 Tablets in Primary IgA NephropathyCompletedPhase 2Chengdu Suncadia Medicine Co., Ltd.NCT06137768Written as HRS-5965
- Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic ImpairmentCompletedPhase 1Chengdu Suncadia Medicine Co., Ltd.NCT06674915Written as HRS-5965 capsules
- Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody TreatmentCompletedPhase 3Chengdu Suncadia Medicine Co., Ltd.NCT06715943Written as HRS-5965 capsule
- Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingPhase 2Chengdu Suncadia Medicine Co., Ltd.NCT06238544Written as HRS-5965 tablets
- Comparison of HRS-5965 Capsules and Tablets in Healthy SubjectsCompletedPhase 1Chengdu Suncadia Medicine Co., Ltd.NCT06490991Written as HRS-5965 tablets;HRS-5965 capsules
- A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyCompletedPhase 3Chengdu Suncadia Medicine Co., Ltd.NCT06593938Written as HRS-5965 capsule
- Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy SubjectsCompletedPhase 1Chengdu Suncadia Medicine Co., Ltd.NCT07040787Written as HRS-5965 Capsules
- A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy SubjectsCompletedPhase 1Chengdu Suncadia Medicine Co., Ltd.NCT07035665Written as HRS-5965 Capsules
- A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy SubjectsCompletedPhase 1Chengdu Suncadia Medicine Co., Ltd.NCT06684041Written as HRS-5965 capsule
- Study of HRS-5965 in Healthy Subjects and Subjects With Renal InsufficiencyCompletedPhase 1Chengdu Suncadia Medicine Co., Ltd.NCT05505955Written as HRS-5965
- A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male VolunteersCompletedPhase 1Chengdu Suncadia Medicine Co., Ltd.NCT06567392Written as [14C] HRS-5965
- Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedPhase 2Chengdu Suncadia Medicine Co., Ltd.NCT06051357Written as HRS-5965 tablets